Urologic oncology · 2025
Stimulated Raman histology as a novel method for rapid pathologic examination of unprocessed, fresh testicular biopsies to determine seminoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maisch Philipp, Wakileh Gamal A, Beck Annika, Mannas Miles P, Horsch Cornelia, Mayer Benjamin, Khalid Florian, Bolenz Christian, Mühlberger Michael
Аннотация
BACKGROUND: Stimulated Raman histology (SRH) is a novel microscopic technique allowing real-time, label free, high-resolution microscopic images of unprocessed, unsectioned tissue. Tissue samples are imaged in the operating room using a mobile SRH microscope. Due to SRH's pseudocoloring, the images appear like conventional H&E staining. Compared to standard histopathologic analysis, formalin fixation, staining and level cutting can be omitted holding potential to decrease the time for diagnosis.
OBJECTIVE: The aim of this prospective feasibility study was to evaluate SRH in the diagnosis of seminoma.
METHODS: Patients with sonographic suspicion of testicular cancer, who underwent surgical exposure of the testis, were included in this study. A small biopsy of the suspicious lesion was separated ex vivo and scanned with an SRH microscope (NIO Laser Imaging System, Invenio Imaging Inc.). Three pathologists were tested on a 40-sample set, including benign and malignant images. We assessed combined accuracy, sensitivity and specificity and concordance (Cohen's Kappa and Fleiss Kappa) for inter-rater reliability.
RESULTS: With the use of SRH the combined accuracy in identifying malignancy was 90%, with an individual pathologist sensitivity range from 79 to 97%. The combined accuracy in identifying benign tissue was 94.4%, with an individual pathologist specificity range from 83 to 100%. Cohen's Kappa for inter-rater reliability had a range from 0.342 to 0.918, which was classified as weak to almost perfect. The scanning time was less than 180 seconds for all tissue samples.
CONCLUSION: Through this first-in-human feasibility study we were able to show that SRH is a reliable and rapid point of care-technique to produce high-resolution images of seminoma, which can be accurately interpreted by pathologists. After further evaluation for all testicular germ cell tumors, SRH may have an impact on clinical decision-making during interventions for testicular cancer.
OBJECTIVE: The aim of this prospective feasibility study was to evaluate SRH in the diagnosis of seminoma.
METHODS: Patients with sonographic suspicion of testicular cancer, who underwent surgical exposure of the testis, were included in this study. A small biopsy of the suspicious lesion was separated ex vivo and scanned with an SRH microscope (NIO Laser Imaging System, Invenio Imaging Inc.). Three pathologists were tested on a 40-sample set, including benign and malignant images. We assessed combined accuracy, sensitivity and specificity and concordance (Cohen's Kappa and Fleiss Kappa) for inter-rater reliability.
RESULTS: With the use of SRH the combined accuracy in identifying malignancy was 90%, with an individual pathologist sensitivity range from 79 to 97%. The combined accuracy in identifying benign tissue was 94.4%, with an individual pathologist specificity range from 83 to 100%. Cohen's Kappa for inter-rater reliability had a range from 0.342 to 0.918, which was classified as weak to almost perfect. The scanning time was less than 180 seconds for all tissue samples.
CONCLUSION: Through this first-in-human feasibility study we were able to show that SRH is a reliable and rapid point of care-technique to produce high-resolution images of seminoma, which can be accurately interpreted by pathologists. After further evaluation for all testicular germ cell tumors, SRH may have an impact on clinical decision-making during interventions for testicular cancer.